FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149402868> ?p ?o ?g. }

• W2149402868 endingPage "32" @default.
• W2149402868 startingPage "1224" @default.
• W2149402868 abstract "Therapeutic efficacy in radioimmunotherapy depends, among other things, on the choice of the radionuclide. The aim of the present study was to determine the most suitable radionuclide for radioimmunotherapy with monoclonal antibody MN-14 to carcinoembryonic antigen in an experimental model of small peritoneal metastases of colorectal origin.In nude mice with intraperitoneal LS174T tumors (diameter, 1-3 mm), the biodistributions of MN-14 labeled with (131)I ((131)I-MN-14), (186)Re-mercaptoacetyltriglycine ((186)Re-MN-14), and (88)Y-diethylenetriaminepentaacetic acid (DTPA) ((88)Y-MN-14) after intravenous and intraperitoneal administration were determined. Subsequently, the therapeutic efficacies of equally toxic activity doses of (131)I-MN-14 (9.25 MBq per mouse), (186)Re-MN-14 (9.25 MBq per mouse), (90)Y-MN-14 (3.15 MBq per mouse), and MN-14 labeled with (177)Lu-DTPA ((177)Lu-MN-14) (8.33 MBq per mouse) after intraperitoneal administration were determined.Each of the radioimmunoconjugates preferentially accumulated in tumor nodules, both after intravenous administration and after intraperitoneal administration. Values for clearance from blood were similar for all radioimmunoconjugates. The uptake of (88)Y-MN-14 in the liver and spleen was significantly higher than the uptake of (131)I-MN-14 or (186)Re-MN-14. Maximal uptake values (mean +/- SD) in tumors were 58 +/- 7 percentage injected dose per gram of tissue (%ID/g) for (131)I-MN-14 (24 h after administration), 83 +/- 19 %ID/g for (186)Re-MN-14 (72 h after administration), and 148 +/- 89 %ID/g for (88)Y-MN-14 (192 h after administration). Dosimetric analysis of the biodistribution data estimated that the radiation doses guided to the tumor by intraperitoneally administered (131)I-MN-14, (186)Re-MN-14, (90)Y-MN-14, and (177)Lu-MN-14 were 150, 100, 45, and 200 Gy, respectively. The median survival time of control mice, treated with unlabeled MN-14, was 42 d, whereas the median survival times of mice treated with (131)I-MN-14, (186)Re-MN-14, (90)Y-MN-14, and (177)Lu-MN-14 were 100 d (range, 58-142; P < 0.0001), 72 d (range, 46-84; P = 0.0002), 82 d (range, 46-142; P < 0.0001), and 136 d (range, 56-142; P < 0.0001), respectively. At the completion of the experiment (142 d after tumor cell inoculation), no residual disease was found in 8 of 9 long-term survivors ((131)I, n = 3; (90)Y, n = 1; and (177)Lu, n = 4).The uptake of (88)Y-MN-14 in small peritoneal LS174T xenografts was higher than the uptake of (131)I-MN-14 or (186)Re-MN-14. The present study indicates that (131)I and (177)Lu are the most suitable radionuclides for the radioimmunotherapy of small peritoneal metastases." @default.
• W2149402868 created "2016-06-24" @default.
• W2149402868 creator A5003890903 @default.
• W2149402868 creator A5006536959 @default.
• W2149402868 creator A5010592696 @default.
• W2149402868 creator A5012764804 @default.
• W2149402868 creator A5034534047 @default.
• W2149402868 creator A5053736639 @default.
• W2149402868 creator A5070554692 @default.
• W2149402868 date "2004-07-01" @default.
• W2149402868 modified "2023-09-26" @default.
• W2149402868 title "Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin." @default.
• W2149402868 cites W1505534997 @default.
• W2149402868 cites W1532412689 @default.
• W2149402868 cites W1544395318 @default.
• W2149402868 cites W1841075178 @default.
• W2149402868 cites W1945013834 @default.
• W2149402868 cites W1972372578 @default.
• W2149402868 cites W1976520588 @default.
• W2149402868 cites W1977461031 @default.
• W2149402868 cites W1987169019 @default.
• W2149402868 cites W1999042510 @default.
• W2149402868 cites W2011832860 @default.
• W2149402868 cites W2021739759 @default.
• W2149402868 cites W2023546298 @default.
• W2149402868 cites W2029940670 @default.
• W2149402868 cites W2032808582 @default.
• W2149402868 cites W2058426435 @default.
• W2149402868 cites W2073610157 @default.
• W2149402868 cites W2080580789 @default.
• W2149402868 cites W2112143065 @default.
• W2149402868 cites W2119940209 @default.
• W2149402868 cites W2132668316 @default.
• W2149402868 cites W2150384126 @default.
• W2149402868 cites W2326555140 @default.
• W2149402868 cites W2116049862 @default.
• W2149402868 cites W45891745 @default.
• W2149402868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15235070" @default.
• W2149402868 hasPublicationYear "2004" @default.
• W2149402868 type Work @default.
• W2149402868 sameAs 2149402868 @default.
• W2149402868 citedByCount "20" @default.
• W2149402868 countsByYear W21494028682012 @default.
• W2149402868 countsByYear W21494028682014 @default.
• W2149402868 countsByYear W21494028682015 @default.
• W2149402868 countsByYear W21494028682016 @default.
• W2149402868 countsByYear W21494028682017 @default.
• W2149402868 countsByYear W21494028682018 @default.
• W2149402868 countsByYear W21494028682019 @default.
• W2149402868 countsByYear W21494028682020 @default.
• W2149402868 crossrefType "journal-article" @default.
• W2149402868 hasAuthorship W2149402868A5003890903 @default.
• W2149402868 hasAuthorship W2149402868A5006536959 @default.
• W2149402868 hasAuthorship W2149402868A5010592696 @default.
• W2149402868 hasAuthorship W2149402868A5012764804 @default.
• W2149402868 hasAuthorship W2149402868A5034534047 @default.
• W2149402868 hasAuthorship W2149402868A5053736639 @default.
• W2149402868 hasAuthorship W2149402868A5070554692 @default.
• W2149402868 hasConcept C112705442 @default.
• W2149402868 hasConcept C121608353 @default.
• W2149402868 hasConcept C126322002 @default.
• W2149402868 hasConcept C159654299 @default.
• W2149402868 hasConcept C185592680 @default.
• W2149402868 hasConcept C202751555 @default.
• W2149402868 hasConcept C203014093 @default.
• W2149402868 hasConcept C2776146153 @default.
• W2149402868 hasConcept C2777387746 @default.
• W2149402868 hasConcept C2777807558 @default.
• W2149402868 hasConcept C2780159080 @default.
• W2149402868 hasConcept C2780931953 @default.
• W2149402868 hasConcept C2989005 @default.
• W2149402868 hasConcept C542903549 @default.
• W2149402868 hasConcept C55493867 @default.
• W2149402868 hasConcept C71924100 @default.
• W2149402868 hasConcept C98274493 @default.
• W2149402868 hasConceptScore W2149402868C112705442 @default.
• W2149402868 hasConceptScore W2149402868C121608353 @default.
• W2149402868 hasConceptScore W2149402868C126322002 @default.
• W2149402868 hasConceptScore W2149402868C159654299 @default.
• W2149402868 hasConceptScore W2149402868C185592680 @default.
• W2149402868 hasConceptScore W2149402868C202751555 @default.
• W2149402868 hasConceptScore W2149402868C203014093 @default.
• W2149402868 hasConceptScore W2149402868C2776146153 @default.
• W2149402868 hasConceptScore W2149402868C2777387746 @default.
• W2149402868 hasConceptScore W2149402868C2777807558 @default.
• W2149402868 hasConceptScore W2149402868C2780159080 @default.
• W2149402868 hasConceptScore W2149402868C2780931953 @default.
• W2149402868 hasConceptScore W2149402868C2989005 @default.
• W2149402868 hasConceptScore W2149402868C542903549 @default.
• W2149402868 hasConceptScore W2149402868C55493867 @default.
• W2149402868 hasConceptScore W2149402868C71924100 @default.
• W2149402868 hasConceptScore W2149402868C98274493 @default.
• W2149402868 hasIssue "7" @default.
• W2149402868 hasLocation W21494028681 @default.
• W2149402868 hasOpenAccess W2149402868 @default.
• W2149402868 hasPrimaryLocation W21494028681 @default.
• W2149402868 hasRelatedWork W1505534997 @default.
• W2149402868 hasRelatedWork W1573890015 @default.

• next